Allergan Settles For $ 200 Million With New York On Opioids | New York News



NEW YORK (AP) – Pharmaceutical company Allergan Finance LLC to pay New York State and two of its counties $ 200 million in a deal that withdraws it from an ongoing lawsuit over the opioids, state attorney general Letitia James said on Wednesday.

Under the agreement with the state and counties of Suffolk and Nassau, Allergan has not admitted any liability.

“For more than two decades, opioids have wreaked havoc among New Yorkers and Americans across the country, causing pain, addiction and death,” James said in a statement. “Our current essay has looked at the role companies like Allergan and its predecessors played in growing this epidemic, profiting while Americans were suffering.”

In a statement, the company said it was “satisfied” to have reached an agreement.

“The settlement will provide up to $ 200 million to resolve opioid issues, as well as to reimburse legal fees and costs that specifically represent the late stage of this lawsuit,” he said. “Allergan previously made the decision to voluntarily discontinue its branded prescription opioid business, which held a minimum market share of less than 1% of prescriptions nationwide.”

Political cartoons

The Allergan deal means Teva Pharmaceuticals remains as a defendant in a lawsuit that has unfolded in Suffolk County in recent months; oral argument was due to begin on Wednesday. Teva and regional drug distribution company Anda are also defendants in a county lawsuit.

In September, the state struck a deal with another company named in the lawsuit, Endo International. Further settlements were reached earlier in the trial process and before it began.

The lawsuit is one of thousands filed by state and local governments, Native American tribes, labor unions, school districts and others seeking to hold pharmaceutical companies accountable for the opioid crisis, which has been linked to more than 500,000 deaths in the United States in the past two decades.

The cases have only started to result in verdicts, and the results have been divided so far. An Oklahoma judge ruled against drugmaker Johnson & Johnson in 2019, but the state Supreme Court overturned that decision in November.

Also in November, a California judge ruled in favor of the drugmakers and a federal judge in Cleveland sided with two Ohio County governments that had claims against drugstore chains.

A trial is over but a judge has yet to rule in a West Virginia case, and a trial is underway in Washington state. Thousands of other cases are awaiting judgment.

Some of the biggest players in the industry, including distributors AmerisourceBergen, Cardinal Health and McKesson and drugmakers Johnson & Johnson, Mallinckrodt Pharmaceuticals and Purdue Pharma have entered into nationwide settlements with potentially much greater cumulative value. to $ 30 billion, with most of the money going to fight the epidemic.

But most of these agreements have not been finalized.

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.



Comments are closed.